1. Home
  2. AYI vs ABVX Comparison

AYI vs ABVX Comparison

Compare AYI & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AYI

Acuity Brands Inc.

HOLD

Current Price

$373.00

Market Cap

11.2B

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$142.16

Market Cap

9.0B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AYI
ABVX
Founded
2001
2013
Country
United States
France
Employees
N/A
N/A
Industry
Building Products
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
11.2B
9.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AYI
ABVX
Price
$373.00
$142.16
Analyst Decision
Buy
Strong Buy
Analyst Count
6
12
Target Price
$395.17
$115.83
AVG Volume (30 Days)
261.7K
1.8M
Earning Date
01-08-2026
08-11-2025
Dividend Yield
0.18%
N/A
EPS Growth
N/A
N/A
EPS
12.53
N/A
Revenue
$4,345,600,000.00
$6,231,374.00
Revenue This Year
$10.96
$6.80
Revenue Next Year
$5.16
N/A
P/E Ratio
$29.72
N/A
Revenue Growth
13.14
N/A
52 Week Low
$216.81
$4.77
52 Week High
$379.17
$148.83

Technical Indicators

Market Signals
Indicator
AYI
ABVX
Relative Strength Index (RSI) 58.21 65.24
Support Level $348.94 $108.53
Resistance Level $374.27 $148.83
Average True Range (ATR) 8.66 7.47
MACD 0.52 2.18
Stochastic Oscillator 83.98 84.29

Price Performance

Historical Comparison
AYI
ABVX

About AYI Acuity Brands Inc.

Acuity is a leading industrial technology company that offers lighting, lighting controls, and intelligent building solutions. Acuity, Inc. designs, manufactures, and brings to market products and services relating to these and other offerings. Acuity, Inc. has two reportable segments: Acuity Brands Lighting and Acuity Intelligent Spaces. ABL sells commercial, architectural, and specialty lighting, including components and control systems. AIS offers building management and audio/visual solutions to help make buildings intelligent.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: